In vitro efficacy of curcumin on Trichomonas vaginalis

Wiener Klinische Wochenschrift

Volumn 126, Issue SUPPL.1, 2014, Pages

  Wachter, Benjamin ^a   Syrowatka, Michael ^a   Obwaller, Andreas ^b   Walochnik, Julia ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Orphanidis Pharma Research GmbH   (Austria)

Author keywords

Curcumin; In vitro; Metronidazole; Protozoa; Trichomonas vaginalis; Turmeric

Indexed keywords

CURCUMIN; METRONIDAZOLE; ANTIPARASITIC AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CURCUMA LONGA; DILUTION; DRUG EFFICACY; IN VITRO STUDY; INCUBATION TIME; MICROTITER PLATE ASSAY; MUCOSA; NONHUMAN; TIME; TRICHOMONAS VAGINALIS; APOPTOSIS; CELL SURVIVAL; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; PHYSIOLOGY; SPECIES DIFFERENCE; TREATMENT OUTCOME;

ANTIPARASITIC AGENTS; APOPTOSIS; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; SPECIES SPECIFICITY; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS;

EID: 84905405671     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-014-0522-8     Document Type: Article

References (52)

1. WHO. Global prevalence and incidence of selected curable sexually transmitted diseases. 2001. http://www.who.int/docstore/hiv/GRSTI/index.htm. Accessed 20 Dec 2013.
2. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductiveage women in the United States, 2001-2004. Clin Infect Dis. 2007;45(10):1319-26. (Pubitemid 351411908)
3. Geelen TH, Hoebe CJ, Dirks A, et al. Low positivity rate after systematic screening for Trichomonas vaginalis in three patient cohorts from general practitioners, STI clinic and a national population-based chlamydia screening study. Sex Transm Infect. 2013;89(6):532-4.
4. Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001-2004 National Health and Nutrition Examination Surveys. Sex Transm Dis. 2009;36(12):738-44.
5. Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006;160(2):151-6. (Pubitemid 43213859)
6. Gottlieb SL, Douglas JM Jr, Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis. 2004;190(6):1059-67. (Pubitemid 39186791)
7. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195(5):698-702.
8. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. 2008;197(4):548-54. (Pubitemid 351321532)
9. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36(1):11-6.
10. Schmid G, Narcisi E, Mosure D, et al. Prevalence of metro-nidazole- resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46(6):545-9. (Pubitemid 32592196)
11. Petrin D, Delgaty K, Bhatt R, et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300-17. (Pubitemid 28197355)
12. Hager WD. Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: case reports of three patients. Sex Transm Dis. 2004;31(6):343-5. (Pubitemid 38691962)
13. Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol. 1999;29(2):199-212. (Pubitemid 29112921)
14. Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis-an emerging problem. N Eng J Med. 1999;341(4):292-3. (Pubitemid 29334535)
15. Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother. 1996;40(5):1121-5. (Pubitemid 26141395)
16. Kuriyama A, Jackson JL, Doi A, et al. Metronidazoleinduced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34(6):241-7.
17. Chacko J, Pramod K, Sinha S, et al. Clinical, neuroimaging and pathological features of 5-nitroimidazole-induced encephalo-neuropathy in two patients: insights into possible pathogenesis. Neurol India. 2011;59(5):743-7.
18. Connor TH, Stoeckel M, Evrard J, et al. The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res. 1977;37(2):629-33. (Pubitemid 8031056)
19. Lindmark DG, Muller M. Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles. Antimicrob Agents Chemother. 1976;10(3):476-82.
20. Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother. 2012;56(9):4800-5.
21. Kazy Z, Puho E, Czeizel AE. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;123(2):174-8. (Pubitemid 41728361)
22. Centers for Disease Control and Prevention, Workowski KA, et al. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1-94.
23. Blaha C, Duchene M, Aspock H, et al. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole- resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother. 2006;57(2):273-8. (Pubitemid 43160169)
24. Kranzler M. Pentamycin - a new option for the treatment of infections with Trichomonas vaginalis? Diploma thesis, University of Vienna; 2011. eBook 978-3-656-14565-32011.
25. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41(13):1955-68. (Pubitemid 41557681)
26. Buescher R, Yang L. Turmeric. In: Lauro GJ, Francis FJ, editors. Natural food colorants. New York: Marcel Dekker; 2000.
27. Perez-Arriaga L, Mendoza-Magana ML, Cortes-Zarate R, et al. Cytotoxic effect of curcumin on Giardia lamblia trophozoites. Acta Trop. 2006;98(2):152-61. (Pubitemid 43783139)
28. Khalafalla RE, Muller U, Shahiduzzaman M, et al. Effects of curcumin (diferuloylmethane) on Eimeria tenella sporozoites in vitro. Parasitol Res. 2011;108(4):879-86.
29. Mimche PN, Taramelli D, Vivas L. The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria. Malar J. 2011;10(Suppl. 1):S10.
30. Shahiduzzaman M, Dyachenko V, Khalafalla RE, et al. Effects of curcumin on Cryptosporidium parvum in vitro. Parasitol Res. 2009;105(4):1155-61.
31. Koide T, Nose M, Ogihara Y, et al. Leishmanicidal effect of curcumin in vitro. Biol Pharm Bull. 2002;25(1):131-3.
32. Changtam C, de Koning HP, Ibrahim H, et al. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem. 2010;45(3):941-56.
33. Allam G. Immunomodulatory effects of curcumin treatment on murine Schistosomiasis mansoni. Immunobiology. 2009;214(8):712-27.
34. Jordan WC, Drew CR. Curcumin - a natural herb with anti-HIV activity. J Natl Med Assoc. 1996;88(6):333.
35. Barthelemy S, Vergnes L, Moynier M, et al. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res Virol. 1998;149(1):43-52. (Pubitemid 28162429)
36. Yadav VS, Mishra KP, Singh DP, et al. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol. 2005;27(3):485-97. (Pubitemid 41428840)
37. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161-8. (Pubitemid 36297021)
38. Wei QY, Chen WF, Zhou B, et al. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta. 2006;1760(1):70-7. (Pubitemid 41790633)
39. Devasena T, Rajasekaran KN, Gunasekaran G, et al. Anticarcinogenic effect of bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione a curcumin analog on DMH-induced colon cancer model. Pharmacol Res. 2003;47(2):133-40. (Pubitemid 36263448)
40. Srivivasan A, Menon VP, Periaswamy V, et al. Protection of pancreatic beta-cell by the potential antioxidant bis-o- hydroxycinnamoyl methane, analogue of natural curcuminoid in experimental diabetes. J Pharm Pharm Sci. 2003;6(3):327-33. (Pubitemid 38097546)
41. Clark CG, Diamond LS. Methods for cultivation of luminal parasitic protists of clinical importance. Clin Microbiol Rev. 2002;15(3):329-41. (Pubitemid 34761343)
42. Fang HY, Chen SB, Guo DJ, et al. Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells. Phytomedicine. 2011;18(8-9):697-703.
43. 2+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Mol Cancer Ther. 2011;10(3):461-71.
44. He ZY, Shi CB, Wen H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Investig. 2011;29(3):208-13.
45. Elad S, Meidan I, Sellam G, et al. Topical curcumin for the prevention of oral mucositis in pediatric patients: case series. Altern Ther Health Med. 2013;19(3):21-4.
46. Manifar S, Obwaller A, Gharehgozloo A, et al. Curcumin gel in the treatment of minor aphthous ulcer: a randomized, placebo-controlled trial. J Med Plants. 2012;11(41):40-5.
47. Heng MC. Wound healing in adult skin: aiming for perfect regeneration. Int J Dermatol. 2011;50(9):1058-66.
48. Helson L. Curcumin (diferuloylmethane) delivery methods: a review. Biofactors. 2013;39(1):21-6.
49. Patel MB, Mandal S, Rajesh KS. Formulation and kinetic modeling of curcumin loaded intranasal mucoadhesive microemulsion. J Pharm Bioallied Sci. 2012;4(Suppl. 1):S81-3.
50. Berginc K, Skalko-Basnet N, Basnet P, et al. Development and evaluation of an in vitro vaginal model for assessment of drug's biopharmaceutical properties: curcumin. AAPS PharmSciTech. 2012;13(4):1045-53.
51. Di Pierro F, Rapacioli G, Di Maio EA, et al. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva(®)), nimesulide, and acetaminophen. J Pain Res. 2013;6:201-5.
52. Kulac M, Aktas C, Tulubas F, et al. The effects of topical treatment with curcumin on burn wound healing in rats. J Mol Histol. 2013;44(1):83-90.